Yet another study is underscoring the benefits of semaglutide, as published in Nature Medicine this week. In a cardiovascular outcomes trial involving 17,604 adults with preexisting cardiovascular disease, overweight, or obesity without diabetes, semaglutide showed a 20% reduction in major adverse cardiovascular events. Those treated with semaglutide sustained weight loss for up to 4 years. Authors say improvements in cardiovascular risk factors can begin with weight loss of just 5%, and in the study, semaglutide was …
Read More